PF 3635659

Drug Profile

PF 3635659

Alternative Names: PF-03635659; PF-3635659

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Oct 2010 Phase II development is ongoing
  • 31 Jan 2010 Phase-II clinical trials in Chronic obstructive pulmonary disease in Germany (PO)
  • 30 Sep 2008 Phase-I clinical trials in Chronic obstructive pulmonary disease in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top